This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2007 Remove Analytical Chemistry Remove Clinical Development Related Topics
Licensing RNA Clinical Research Small Molecule DNA Pharmaceuticals FDA Approval Trials Treatment Drug Development More Related Topics >
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

MARCH 7, 2023

Linda Powers, CEO, Northwest Biotherapeutics Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. Other roles include Head of Biology at TopoTarget A/S, where she was responsible for the pre-clinical development of belinostat which went on to gain FDA approval to treat peripheral T-cell lymphoma.

International 246
International Science Pharmaceuticals DNA 246
article thumbnail

BioSpace Movers & Shakers, Nov. 6

The Pharma Data

NOVEMBER 5, 2020

Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007.

Analytical Chemistry 40
Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024